Seeing Is Believing
Currently, out of the existing stock ratings of Keay Nakae - 98 which are a Buy (78.4%), 19 which are a Hold (15.2%), 8 which are a Sell (6.4%)
Analyst Keay Nakae works at CHARDAN CAPITAL and is covering the Healthcare sector with 208 price targets and ratings displayed on 30 stocks.
Keay Nakae's average stock forecast success ratio is 38.21% with an average time for price targets to be met of 63.29 days.
Most recent stock forecast was given on PRQR, ProQR Therapeutics N.V at 08-Nov-2023.
Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/8/2021. The price target of $13 was fulfilled within 1 day with a profit of $2.81 (17.77%) receiving and performance score of 177.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
6
$3.97 (195.57%)
6
2 months 23 days ago
0/8 (0%)
$3.75 (150.13%)
Buy
4 months 1 days ago
0/4 (0%)
$2.4 (80.25%)
Buy
6
$3.97 (195.57%)
6
4 months 29 days ago
0/3 (0%)
$4.35 (169.15%)
Hold
5
$2.97 (146.31%)
1 years 10 months 3 days ago
0/1 (0%)
$2.11 (73.01%)
Buy
10
2 years 5 months 7 days ago
0/2 (0%)
$6.88 (220.99%)
Which stock is Keay Nakae is most bullish on?
Which stock is Keay Nakae is most reserved on?
What Year was the first public recommendation made by Keay Nakae?